Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 Next >
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Appoints Robert Watson as Chairperson of the Board
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.